LONDON, UK — 1st October 2024, Access Infinity, an award-winning market access consultancy and digital solutions firm, has had its emissions reduction targets approved by the Science Based Targets initiative (SBTi) as consistent with levels required to meet the goals of the Paris Agreement.
Access Infinity has long upheld strong practices in managing greenhouse gas emissions from its own operations (Scope 1 and 2), aligning with the necessary standards to limit global warming to 1.5°C. As part of its ongoing commitment to sustainability, the company now focuses on further reducing emissions across its value chain (Scope 3).
With a new Scope 3 target that meets the SBTi criteria for ambitious value chain goals, Access Infinity is setting a benchmark for climate leadership and sustainable growth.
Access Infinity’s Partner, Nick Proctor shares his enthusiasm on the company’s latest achievement:
Through its commitment to the SBTi, Access Infinity seeks to reduce their greenhouse gas emissions to be consistent with keeping warming below the most dangerous levels.
For more information about Access Infinity and its commitment to climate action, please visit: SBTi website.
What are Science-based targets?
Science-based targets are emissions reduction targets in line with what the latest climate science says is needed to meet the goals of the Paris Agreement – to limit global warming to well-below 2°C above pre-industrial levels and pursue efforts to limit warming to 1.5°C. Science-based targets are emissions reduction goals in line with what the latest climate science says is needed to prevent the worst impacts of climate change. Science-based targets show companies how much and how quickly they need to reduce their greenhouse gas emissions in order to be consistent with keeping warming below the most dangerous levels.
What is the Science-based targets initiative (SBTi)
The SBTi is a collaboration between CDP, the United Nations GlobalCompact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi defines and promotes best practice in science-based target setting and independently assesses companies’ targets.
About Access Infinity
Access Infinity exists to help pharma companies overcome market access challenges. Founded in 2014, the company began as a consulting firm to guide pharma businesses in developing and implementing effective market access and pricing strategies and continues to be a leader in the space. It has since introduced market-redefining digital tools, NUROTM, Access HubTM and Evidence Library to help market access teams work smarter, faster, and more efficiently with valuable insights at their fingertips.
With offices in London, Hyderabad and Manchester, Access Infinity is experiencing rapid growth as it continues to transform and simplify market access for pharmaceutical organisations globally. Clients include many of the pharmaceutical industry’s leading companies such as Astra Zeneca, GSK and Pfizer. In 2023 Access Infinity received a Bronze Stevie® Award in the Technical Innovation of the Year category for organisations with up to 100 employees. The business was also recognised in GHP magazine’s Healthcare & Pharmaceutical Awards, winning “Most innovative digital pharmaceuticals platform 2023 UK”.
Email: louise@accessinfinity.com
